(FLGT) Fulgent Genetics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FLGT) Fulgent Genetics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Fulgent Genetics, Inc. BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Oncology panels
Fulgent Genetics, Inc.’s oncology panels sit in a Star role because they target cancer identification in a precision oncology market that keeps expanding. The company offers broad, clinically used panel testing, so demand can recur as patients move through diagnosis, treatment selection, and monitoring. In 2025, precision oncology adoption stayed strong across U.S. labs and health systems, supporting volume growth for panel-based testing.
Solid tumor molecular profiling
Solid tumor molecular profiling is a core Fulgent Genetics cancer test and fits a Stars slot because oncology keeps shifting toward biomarker-driven care. Fulgent Genetics reported 2024 revenue of about $286 million, while the broader molecular diagnostics market is still growing at double-digit rates, supporting demand. As more solid-tumor cases need faster, deeper gene panels, this line stays high-need and high-growth.
Rapid whole genome testing for NICU and PICU
Fulgent Genetics, Inc.'s rapid whole genome testing for NICU and PICU is a Star because it targets critically ill newborns and children where hours matter. Published NICU/PICU studies show diagnostic yields around 30% to 50%, and turnaround times can be under 48 hours, making the test both clinically high value and time-sensitive. As sequencing gets faster and more embedded in care, this category should keep expanding.
Beacon carrier screening
Beacon carrier screening targets inherited conditions and fits a broad reproductive genetics market that keeps expanding as preconception and prenatal testing rise. For Fulgent Genetics, Inc., the offer has scale potential because it can be sold through OB-GYN, fertility, and health system channels, with repeat use tied to family planning. In BCG terms, that mix of market growth and channel breadth supports a Star profile if share keeps rising.
- Inherited-condition testing
- Broad reproductive demand
- Multi-channel scale potential
Comprehensive exome and whole genome testing
Fulgent Genetics’ exome and whole genome tests are a Star because they fit rare-disease and hard-to-diagnose cases, where broader sequencing can find variants single-gene panels miss. Global demand keeps rising as sequencing costs fall and more clinicians use genomic testing in routine care.
- Best fit for rare and complex cases
- Broader reach than fixed panels
- Demand grows with lower sequencing costs
These tests also support recurring clinical use, so adoption can expand as payer coverage and physician comfort improve.
Fulgent’s Growth Stars: Oncology and Rapid NICU Sequencing
Fulgent Genetics, Inc.'s Stars are oncology panels, rapid NICU/PICU sequencing, carrier screening, and exome/whole genome tests because each ties to a growing clinical need and can scale with more testing use. Fulgent Genetics, Inc. reported about $286 million in 2024 revenue, while NICU/PICU sequencing studies show 30% to 50% diagnostic yields and under-48-hour turnaround.
| Star area | Why it fits |
|---|---|
| Oncology panels | High-growth precision oncology |
| NICU/PICU WGS | 30%–50% yield; <48h |
What is included in the product
Detailed Word Document
Fulgent Genetics BCG Matrix: maps its testing and sequencing businesses to guide invest, hold, or divest decisions.
Editable Excel File
One-page Fulgent Genetics BCG Matrix for fast portfolio clarity and strategy decisions
Reference Sources
Shows the source trail behind Fulgent Genetics, Inc. data, boosting credibility and making investment decisions easier to verify.
Cash Cows
Flow cytometry
Flow cytometry is a mature lab service for cell analysis and malignancy monitoring, so it fits a Cash Cow in Fulgent Genetics, Inc.'s BCG Matrix. It supports steady repeat demand from oncology follow-up and routine diagnostics, which usually means stable utilization and dependable cash generation.
FISH testing
FISH testing is a mature fluorescence in situ hybridization method used to spot specific DNA sequences in cancer, prenatal, and rare-disease workflows. Its long clinical track record and routine lab use support steady demand, which fits a Cash Cow role in Fulgent Genetics, Inc.'s BCG Matrix. In a stable segment like this, the main value is dependable cash generation rather than high growth.
Immunohistochemistry
Immunohistochemistry is a mature cash cow for Fulgent Genetics, Inc., used to visualize cellular antigens in pathology and oncology. In 2025, it stayed standard in tumor workups because it is fast, repeatable, and operationally efficient. That makes it a steady-margin service with limited reinvestment needs.
Cytogenetics
Cytogenetics is Fulgent Genetics, Inc.’s core chromosomal analysis service, used in established lab workflows to detect chromosomal anomalies. It fits the Cash Cows quadrant because demand is steady, the test menu is mature, and growth is usually modest but dependable.
Its value is in routine volume and clinical necessity, not rapid expansion. In 2025, Fulgent Genetics reported full-year revenue of about $300 million, and the stable testing base helped support recurring diagnostics income across core services.
For BCG analysis, Cytogenetics acts as a low-growth, high-reliability asset: it keeps utilization up, supports physician and hospital relationships, and anchors revenue in a proven workflow. That makes it a dependable cash generator rather than a growth driver.
- Core chromosomal anomaly testing
- Low growth, steady clinical demand
- Supports recurring diagnostics revenue
- Best viewed as a cash generator
Hematopoietic and solid tumor molecular testing
Fulgent Genetics, Inc.’s hematopoietic and solid tumor molecular testing fits Cash Cows: it feeds repeat hospital and lab workflows, so revenue comes from steady case volume, not big new installs. In 2025, the segment sat in a mature lab-services market while the company kept focusing on margin discipline and utilization, which matters more than fast top-line growth.
- Recurring, protocol-based testing
- Hospital and lab reorder demand
- Volume-led, margin-sensitive economics
- Low growth, steady cash generation
Fulgent Genetics’ Steady Cash Cows Anchor ~$300M in 2025 Revenue
Fulgent Genetics, Inc.’s Cash Cows are mature lab services like cytogenetics, FISH, IHC, and flow cytometry, where demand is steady and reinvestment needs are low. In 2025, Fulgent Genetics reported about $300 million in full-year revenue, showing the value of its stable testing base. These services matter more for reliable cash flow than fast growth.
| Metric | 2025 |
|---|---|
| Full-year revenue | ~$300M |
| Cash Cow tests | Mature core services |
| Growth profile | Low to modest |
Preview Before You Purchase
Fulgent Genetics, Inc. Reference Sources
This Fulgent Genetics, Inc. BCG Matrix preview is the exact document you’ll receive after purchase. No placeholders or hidden changes—just the same professionally formatted file shown here. Once purchased, it’s ready for immediate download, use, and sharing.
Dogs
SARS-CoV-2 RT-PCR testing
SARS-CoV-2 RT-PCR testing was a major COVID-19 revenue driver for Fulgent Genetics, Inc., but demand has collapsed from pandemic peaks as routine screening faded. In 2024, the company’s revenue was far below 2021 highs, showing this line is now a low-growth legacy business. In a BCG Matrix, it fits "Dog": weak growth and limited strategic pull.
SARS-CoV-2 antigen testing
SARS-CoV-2 antigen testing is a Dogs business for Fulgent Genetics, Inc. because demand has fallen with pandemic normalization, and pricing is under heavy pressure. The U.S. COVID-19 public health emergency ended on May 11, 2023, and this product line now competes in a much smaller, lower-margin market.
SARS-CoV-2 next-generation sequencing
SARS-CoV-2 next-generation sequencing is a narrow "Dog" for Fulgent Genetics, Inc., because it serves one pathogen and a limited research-heavy use case. Pandemic demand peaked in 2020-2021, and by 2025 this category had far less volume and weaker growth than broad hereditary testing. With COVID-19 testing and surveillance normalizing, long-term upside looks limited.
SARS-CoV-2 diagnostic franchise
Fulgent Genetics, Inc.’s SARS-CoV-2 diagnostic franchise used PCR, antigen, and other formats, and it was a key revenue driver in earlier pandemic quarters. With COVID demand normalized, the line is now structurally lower growth and likely a Dogs-style asset in the BCG Matrix. Recent filings show the franchise has shrunk to a small part of sales, while Fulgent’s core 2025–2026 focus shifted back to oncology and inherited disease testing.
- Early pandemic: material revenue contributor
- Now: low-growth, low-priority segment
- Multiple test formats, but demand faded
Picture Genetics direct-to-patient testing
Picture Genetics is Fulgent Genetics, Inc.’s patient-initiated testing brand, but consumer genetics is crowded, price-driven, and hard to scale. In FY2025 terms, that weak market position and limited share fit a BCG Dog: low growth, low share, and weak capital efficiency. The asset looks more like an option than a core engine.
- Low share in a crowded market
- Weak scale economics
- Best kept lean
Fulgent’s COVID Testing Franchises: A Shrinking Dog
Fulgent Genetics, Inc.’s COVID testing franchise is now a Dog: demand fell sharply after the May 11, 2023 public health emergency ended, and FY2025 sales were far below pandemic peaks. With PCR, antigen, and sequencing tied to a shrinking market, the segment has weak growth, low share, and little capital pull.
| Metric | Dogs view |
|---|---|
| COVID testing demand | Down since 2023 |
| FY2025 role | Low-priority |
Question Marks
Helio blood-based early cancer detection
Fulgent’s Helio Health partnership keeps blood-based early cancer detection in a high-growth question mark: the global liquid biopsy market was about $7.5 billion in 2025 and is still expanding fast. Commercial share is still being built, so revenue is likely early-stage, but the long-term market is large. For BCG, this is a Question Mark with strong upside, but it still needs adoption and reimbursement wins.
Newborn genetic analysis panel
Newborn genetic analysis panel sits in the Question Mark zone: clinically important, but adoption still depends on workflow fit and lab validation. Fulgent Genetics, Inc. reported $289.0 million in 2025 revenue, yet it did not break out this panel’s sales, so the category’s scale is still unclear. The market has real growth potential, but hospital integration and reimbursement will decide how fast it scales.
Front-line test for ataxia-related variants
Fulgent Genetics' front-line ataxia-related variant test is a narrow, single-indication offer, so it fits a Question Mark: low share now, but upside if neurologists adopt it. In Fulgent Genetics' latest filed FY2024 report, revenue was $320.5 million, and the hereditary disease mix was still small, so this niche has not yet reached scale. The commercial runway still depends on referral growth, payer coverage, and whether ataxia panels move into first-line use.
Mutation and repeat expansion testing
Mutation and repeat expansion testing fits Fulgent Genetics, Inc.'s question-mark bucket because it serves narrow inherited and neurologic niches, where precision medicine is lifting demand. Still, these assays compete against broader multi-panel menus from larger labs, so share is hard to pin down. The upside is real, but adoption and scale remain the key test.
- High clinical need, narrow use case
- Precision medicine can support growth
- Share pressure from larger panels
Research service tests
Fulgent Genetics, Inc.'s research service tests stay in question-mark territory: demand can grow, but the field is still crowded, fragmented, and price-sensitive.
That means the line can scale if Fulgent wins more biotech and pharma work, but it needs steady investment in sales, lab capacity, and turnaround speed to gain share.
- Growth potential: real, but uneven
- Competition: high and fragmented
- Position: still a question mark
Fulgent’s Growth Questions: Big Market, Small Share
Fulgent Genetics, Inc.’s question marks still need share gains: Helio Health sits in a liquid biopsy market near $7.5 billion in 2025, while Fulgent Genetics, Inc. booked $289.0 million revenue in 2025. Newborn, ataxia, and repeat-expansion tests are clinically useful, but sales are still too small or unbroken out to show scale.
| Item | 2025/2026 data | BCG view |
|---|---|---|
| Helio Health | $7.5B market | Question Mark |
| Fulgent Genetics, Inc. | $289.0M revenue | Low share |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.